We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Long-acting drug delivery formulations
- Types of drug-eluting implants
- Representative drawings of various IDDSs
- Advantages and disadvantages of IDDSs
- The novel microchip and pedicle screw IDDS
- Description of various types of IDDSs
- Advantages and disadvantages of IDDSs
- The GLIADEL® Wafer
- Meta analysis
- Overall survival for HGG patients undergoing initial surgery
- GLIADEL® Wafer (carmustine implant) adverse events
- Implantable injectable gels
- Norplant Silicone Implant (5 years)
- Poly lactic-co-glycolic acid (PLGA) (1)
- Poly lactic-co-glycolic acid (PLGA) (2)
- Naltrexone: implantable pellet
- Commercial biodegradable microparticle products
- Single emulsion solvent evaporation method
- Biodegradable microparticles (1)
- Biodegradable microparticles (2)
- Mice plasma levels of ivacaftor
- Learning outcomes
- Thank you
Topics Covered
- Types of drug eluting implants
- Advantages and disadvantages of IDDS’s
- GLIADEL Wafer
- Implantable injectable gels
- PLGA
- Naltrexone
- Microparticles
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Salem, A.K. (2022, July 31). Drug-eluting implants [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 7, 2024, from https://doi.org/10.69645/JQDH3474.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Aliasger K. Salem has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Other Talks in the Series: Drug Delivery
Transcript
Please wait while the transcript is being prepared...
0:00
The title of my talk is going to
be drug-eluting implants.
My name is Aliasger K. Salem.
I'm the Bighley Chair
and Professor of
Pharmaceutical Sciences at
the University of Iowa
College of Pharmacy.
0:15
With this presentation,
I'm going to talk about
drug-eluting implants and
how they can provide
sustained drug delivery.
In the field of drug delivery,
the most commonly used
treatments have traditionally
traditionally been
systemic delivered drugs
using oral or intravenous
administration.
The problems associated
with this type of
delivery is that the
drug concentration is
controlled by
first-class metabolism.
Therefore, may not always remain
within the therapeutic window.
Implantable drug
delivery systems,
which during this talk we
will also refer to as IDDs,
are an excellent alternative
to traditional delivery
because they offer
the ability to
precisely control
the drug release,
deliver drugs locally
to the target tissue,
and avoid the toxic side
effects often experienced
with systemic administration.
Since the creation
of the first FDA
approved IDDS in 1990,
there has been a surge
in research devoted to
fabricating and testing
novel IDDS formulations.
The versatility of these
systems is evident
when looking at the various
biomedical applications
that utilize IDDSs.
In this presentation,
I'm going to give
some detailed examples of
IDDs and how they work,
and I'm going to talk
about their advantages,
their disadvantages and
then give an overview
of future prospects.
When it comes to long-acting
drug delivery formulations,
the advantages of
long-acting formulations
over conventional
dosage forms include
the ability to avoid sharp
fluctuations in drug concentration,
avoid sub-therapeutic/toxic
doses
and improve patient compliance
and adherence to treatment.
If you look at this
graph for an example,
you can see that
when you're giving
single dose, immediate
release formulations,
you have periods
where you're above
that minimum safe concentration,
periods where you're below
the minimum effective
concentration
and periods of time
where you're within
that ideal region.
If you have a sustained
release formulation
or a zero-order controlled
release formulation,
you can stay within that
range that is always below
the minimum safe concentration
and above the minimum
effective concentration,
which is an ideal profile
for a sustained
release formulation.
The types of drug-eluting
implants that are available